Norris Perne & French LLP MI Acquires 100 Shares of Stryker Co. (NYSE:SYK)

Norris Perne & French LLP MI increased its holdings in Stryker Co. (NYSE:SYK) by 3.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,789 shares of the medical technology company’s stock after purchasing an additional 100 shares during the quarter. Norris Perne & French LLP MI’s holdings in Stryker were worth $1,004,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of SYK. Cetera Investment Advisers increased its stake in shares of Stryker by 2.5% in the second quarter. Cetera Investment Advisers now owns 89,948 shares of the medical technology company’s stock worth $30,605,000 after buying an additional 2,220 shares during the period. Sanctuary Advisors LLC purchased a new position in shares of Stryker during the second quarter valued at approximately $19,301,000. Centaurus Financial Inc. lifted its stake in Stryker by 11.3% in the second quarter. Centaurus Financial Inc. now owns 1,047 shares of the medical technology company’s stock worth $356,000 after acquiring an additional 106 shares during the period. Appleton Partners Inc. MA raised its holdings in Stryker by 0.7% in the 3rd quarter. Appleton Partners Inc. MA now owns 27,822 shares of the medical technology company’s stock worth $10,051,000 after purchasing an additional 182 shares in the last quarter. Finally, American National Bank & Trust boosted its stake in shares of Stryker by 14.3% during the 3rd quarter. American National Bank & Trust now owns 34,200 shares of the medical technology company’s stock valued at $12,355,000 after purchasing an additional 4,281 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Down 0.2 %

Shares of SYK stock opened at $390.48 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The stock has a market capitalization of $148.86 billion, a P/E ratio of 50.32, a P/E/G ratio of 2.68 and a beta of 0.95. The firm’s 50 day moving average is $376.55 and its 200 day moving average is $362.18.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.86% and a net margin of 13.25%. During the same period in the prior year, the company posted $3.46 EPS. Research analysts expect that Stryker Co. will post 13.53 earnings per share for the current year.

Stryker Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be given a dividend of $0.84 per share. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. This is a positive change from Stryker’s previous quarterly dividend of $0.80. Stryker’s dividend payout ratio is presently 43.30%.

Insider Transactions at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the company. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research report on Tuesday, January 7th. JPMorgan Chase & Co. upped their price target on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a research note on Wednesday. The Goldman Sachs Group raised their price objective on Stryker from $384.00 to $427.00 and gave the company a “neutral” rating in a research report on Thursday. Robert W. Baird upped their target price on shares of Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Finally, Morgan Stanley raised shares of Stryker from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $370.00 to $445.00 in a research note on Monday, December 2nd. Five analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and an average target price of $416.40.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.